Strides receives FDA OK for adenosine and meloxicam
This article was originally published in Scrip
Strides Arcolab has received US FDA approval for its ANDA for adenosine injection 3mg/ml, packaged in 6mg/2ml single dose vials, and meloxicam tablets 7.5mg and 15mg. Adenosine injection, a cardiovascular agent, is a generic version of Astellas Pharma's Adenocard, while meloxicam tablets are a generic version of Boehringer Ingelheim's non-steroidal anti-inflammatory drug, Mobic. Strides now has approval for 16 sterile and 12 oral products.
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.